Optometry & Visual Performance 156 Volume 14 | Issue 2 | June 2026 Eye Hero Eye Hero is a gamified, app-based dichoptic vision therapy platform, developed by Hundred Vision and designed for home use in children with amblyopia and mild strabismus. It is downloaded as an app and used on a tablet or computer screen. Children wear red-green anaglyph glasses to separate the images presented to each eye. The amblyopic eye receives high-contrast stimuli, while the fellow eye receives attenuated input through the red filter, and interactive games are played during therapy. Eye Hero is commercially available but is not FDA-cleared. The platform operates on dichoptic principles, presenting complementary stimuli to each eye under conditions that require binocular cooperation to reduce interocular suppression and to promote functional binocularity. A proprietary adaptive algorithm continuously adjusts game content and difficulty in real time based on the child’s accuracy, reaction time, and consistency. Importantly, Eye Hero is designed to target not only visual acuity but a broader range of visual functions, including oculomotor control, selective attention, and handeye coordination. This reflects the understanding that amblyopia is a multisystem neurodevelopmental disorder. The prescribed dose is 30 minutes per day, five days per week, for six months. The clinical evidence comes from a prospective non-randomized controlled study that had 29 children ages 7–13 with anisometropic amblyopia were enrolled: 14 in the treatment group and 15 age- and sex-matched typically developing controls who received no intervention.3 What distinguished this study from most amblyopia trials was its multimodal assessment approach. They measured not only visual acuity and stereopsis but also oculomotor function via videonystagmography, motor proficiency via the BOT-2, and postural stability via the Sensory Organization Test. Visual acuity in the amblyopic eye improved progressively across all four time points, with a total gain of approximately 1.5 lines at six months. Stereoacuity improved from a median of 300 arcseconds at baseline to 45 arcseconds at six months. That is a three-octave gain in binocular depth perception. Oculomotor improvements were equally compelling: saccadic latency decreased from 235 ms to 213 ms, smooth pursuit gain improved across all tested frequencies, and optokinetic gain improved from 0.65 to 0.73 in the amblyopic eye. Perhaps most strikingly, BOT-2 upper extremity coordination scores improved by nearly 40%, from 22.55 to 31.00 (p<0.001), and balance scores improved significantly as well. Controls showed no significant changes in any measured domain. Bynocs Bynocs is a cloud-based dichoptic vision therapy platform designed to treat amblyopia through gamified, computer-based training. It runs in a standard internet browser on any screen larger than 11 inches and requires only an internet connection and a pair of red-blue anaglyph glasses. Bynocs has been studied in children as young as 4 years old and in adults up to 30 years old, across multiple amblyopia types, including anisometropic, isometropic bilateral, strabismic, and deprivational amblyopia. The platform uses red-blue anaglyph glasses to separate the images presented to each eye. What distinguishes Bynocs is its figure-ground stimulus design: the key game elements requiring active attention are visible only to the amblyopic eye, while the fellow eye sees the broader game environment. Color contrast between the two eyes is automatically adjusted so that the weaker eye perceives highercontrast stimuli, and the stimuli presented to the amblyopic eye undergo continuous dynamic adjustments in size, spatial frequency, temporal frequency, and target speed as the patient improves. A notable feature is built-in remote supervision. Patients are monitored by a Bynocs optometrist via video call, with visual performance and compliance assessed after every ten sessions. The prescribed dose is 30 minutes per day, five days per week for six weeks. There was a retrospective study from Mumbai analyzing data from 161 children ages 4–13, including both anisometropic (127 children) and isometropic bilateral amblyopia (34 children), a population typically excluded from other dichoptic studies.6 With no control group, BCVA in the amblyopic eye improved by a mean of 0.39 logMAR, approximately four lines. The percentage of patients without measurable stereopsis dropped from 65.8% to 11.8%, and the percentage without flat fusion on Worth 4-dot fell from 61.5% to 6.3%. One limitation worth noting is that stereopsis was measured using the “Bynocs Randot Test,” the platform’s built-in tool, which raises a potential conflict of interest when assessing the platform’s outcomes. A study published in the Journal of Pediatric Ophthalmology and Strabismus by Ganesh,7
RkJQdWJsaXNoZXIy MjEyMDQ0Nw==